Schizophrenia Research Forum - A Catalyst for Creative Thinking
Home Profile Membership/Get Newsletter Log In Contact Us
 For Patients & Families
What's New
Recent Updates
SRF Papers
Current Papers
Search All Papers
Search Comments
Research News
Conference News
Plain English
Current Hypotheses
Idea Lab
Online Discussions
Virtual Conferences
What We Know
Animal Models
Drugs in Trials
Research Tools
Community Calendar
General Information
Member Directory
Researcher Profiles
Institutes and Labs
About the Site
SRF Team
Advisory Board
Support Us
How to Cite
Fan (E)Mail
The Schizophrenia Research Forum web site is sponsored by the Brain and Behavior Research Foundation and was created with funding from the U.S. National Institute of Mental Health.
Online Discussions

Updated 11 November 2009
Printable version

Forum Discussion: How Might Dysbindin Affect the Schizophrenic Brain?

View article

In our Forum Discussion “journal club” series, the editors of Neuropsychopharmacology provide access to the full text of a recent article. An introduction by Monsheel Sodhi, Assistant Professor, Department of Psychiatry and Behavioral Neurobiology, UAB, gets us started, and then it's up to our readers to share their ideas and insights, questions, and reactions to the selected paper. So read on….

Donohoe G, Frodl T, Morris D, Spoletini I, Cannon DM, Cherubini A, Caltagirone C, Bossù P, McDonald C, Gill M, Corvin AP, Spalletta G. Reduced Occipital and Prefrontal Brain Volumes in Dysbindin-Associated Schizophrenia. Neuropsychopharmacology. 2009 Sep 30. [Epub ahead of print]. Abstract

Our thanks to Nature Journals for allowing this article to be posted for discussion at SRF.

View Comments By:
Marquis Vawter — Posted 15 December 2009
Gary Donohoe — Posted 17 December 2009
Joel Kleinman — Posted 13 February 2010

Background Text
By Monsheel Sodhi, Assistant Professor, Department of Psychiatry and Behavioral Neurobiology, University of Alabama at Birmingham

This paper reports new data that may increase interest in the move toward using genetic markers to predict more focused phenotypes in schizophrenia. The heritability of morphological changes in the brains of schizophrenia patients has been found to be high (Peper et al., 2007). Therefore, the authors of the current paper have investigated one of the candidate genes for schizophrenia identified by positional cloning, the gene encoding dystrobrevin-binding protein 1 (dysbindin).

There have been many case-control studies published that have produced conflicting data on the genetic association between dysbindin and schizophrenia; for example, at least 19 studies have been positive (see However, in the current paper, the authors show that the gene encoding dysbindin is associated with altered brain morphology, as measured by voxel-based morphometry. Subjects carrying a risk haplotype comprising the dysbindin SNPs P1655 (rs2619539), P1635 (rs3213207), and SNP66961 (rs2619538) (abbreviated to C-A-T) have reductions in gray matter volumes of the right dorsolateral prefrontal cortex and left occipital cortex.

The same risk haplotype may be a marker in a subset of the schizophrenia population who have a specific combination of symptoms due to particular structural and/or developmental defects in the brain. These morphological changes could explain certain symptoms exhibited by patients, particularly cognitive and negative ones, which have previously been associated with the C-A-T haplotype of dysbindin (Corvin et al., 2008).

Dysbindin is expressed in forebrain glutamate neurons. It interacts with proteins involved in the presynaptic trafficking of vesicles and exocytosis. In fact, mice with a null mutation of the dysbindin gene have been reported to show impaired spatial working memory relative to wild-type controls (Jentsch et al., 2009).

Taken together, these data indicate that dysbindin impacts brain functions such as working memory. This may be due to impaired brain development via dysregulation of presynaptic glutamatergic transmission. Therefore, functional genetic variation of dysbindin could contribute to some of the more devastating symptoms experienced by patients with schizophrenia.

If these findings are replicated, many questions will need to be addressed. For instance, by what mechanism(s) could dysbindin change gray matter volume in these brain regions? Could patients who have schizophrenia and abnormal gray matter volume in these specific regions have a subtype of schizophrenia that is attributable to altered dysbindin?

Peper JS, Brouwer RM, Boomsma DI, Kahn RS, Hulshoff Pol HE. Genetic influences on human brain structure: a review of brain imaging studies in twins. Hum Brain Mapp. 2007;28(6):464-73. Abstract

Corvin A, Donohoe G, Nangle JM, Schwaiger S, Morris D, Gill M. A dysbindin risk haplotype associated with less severe manic-type symptoms in psychosis. Neurosci Lett. 2008;431(2):146-9. Abstract

Jentsch JD, Trantham-Davidson H, Jairi C, Tinsley M, Cannon TD, Lavin A. Dysbindin modulates prefrontal cortical glutamatergic circuits and working memory function in mice. Neuropsychopharmacology. 2009 July 29. Abstract

Comments on Online Discussion
Comment by:  Marquis Vawter
Submitted 15 December 2009 Posted 15 December 2009

The article by Donohoe et al. asks several questions about...  Read more

View all comments by Marquis Vawter

Comment by:  Gary Donohoe
Submitted 17 December 2009 Posted 17 December 2009

Interest in dysbindin as a candidate gene for...  Read more

View all comments by Gary Donohoe

Comment by:  Joel Kleinman
Submitted 13 February 2010 Posted 13 February 2010

The Donohoe et al. Neuropsychopharmacology paper is an...  Read more

View all comments by Joel Kleinman
Submit a Comment on This Online Discussion
Make a comment on this live discussion. 

If you already are a member, please login.
Not sure if you are a member? Search our member database.

*First Name  
*Last Name  
Country or Territory  
*Login Email Address  
*Confirm Email Address  
*Confirm Password  
Remember my Login and Password?  
Get SRF newsletter with recent commentary?  
Enter the code as it is shown below:
This code helps prevent automated registrations.

Please note: A member needs to be both registered and logged in to submit a comment.


(If coauthors exist for this comment, please enter their names and email addresses at the end of the comment.)


SRF News
SRF Comments
Text Size
Reset Text Size
Live Discussion FAQs

Webinar: A Webinar is a seminar conducted remotely over the Web. Attendees view the slides through their Web browser and hear the presentations over their own telephones.

Registration: All participants are to register by clicking on the "Register for the Webinar" link.

Access: After you register, you will receive an e-mail with a link to the Webinar and a phone number.
New Schizophrenia Fact Sheet for Patients and Families

Latest BBRF Research Breakthroughs

Visit our Facebook page and our Blog.

Support the Brain & Behavior Research Foundation Today.

Research Participants
Copyright © 2005- 2016 Schizophrenia Research Forum Privacy Policy Disclaimer Disclosure Copyright